The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in R/R DLBCL?

Jan 28, 2021
Share:

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Giuseppe Gritti, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?

Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in R/R DLBCL?

In this video, Gritti discusses the data from a study evaluating polatuzumab vedotin, venetoclax, and rituximab combined treatment in patients with R/R DLBCL.

Share: